A Randomized, Placebo-controlled, Prospective, Single-blind, Single Center Phase 2 Study of the Efficacy and Safety of SANGUINATE for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant
Latest Information Update: 30 May 2018
At a glance
- Drugs PEG-haemoglobin carbon monoxide (Primary)
- Indications Delayed graft function
- Focus Adverse reactions; Therapeutic Use
- Sponsors Prolong Pharmaceuticals
- 23 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Feb 2016 New trial record